Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines

doi:10.5662/wjm.v15.i4.107643

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (92)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

HTML

Tables (1-2)

Sum=90

Dec 20, 2025 (publication date) through Aug 4, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Methodol. Dec 20, 2025; 15(4): 107643
Published online Dec 20, 2025. doi: 10.5662/wjm.v15.i4.107643

Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines

Mohamed Mahmoud Hafez, Ibrahim Halil Bahcecioglu, Mehmet Yalniz, Karim Abdelwahab Kouta, Ahmed Tawheed

Mohamed Mahmoud Hafez, Faculty of Medicine, Helwan University, Cairo 11795, Egypt

Ibrahim Halil Bahcecioglu, Mehmet Yalniz, Ahmed Tawheed, Department of Gastroenterology, Firat University, Elazig 23119, Türkiye

Karim Abdelwahab Kouta, Department of Gastroenterology, Al-Shifaa Medical Complex, Egypt Healthcare Authority, Port Said 42534, Būr Sa‘īd, Egypt

Ahmed Tawheed, Department of Gastroenterology, Al Emadi Hospital, Doha 50000, Qatar

Author contributions: All authors have contributed to this article and have approved the final version of the manuscript; Tawheed A designed the overall concept and outline of the manuscript; Hafez MM and Yalniz M revised the manuscript, Bahcecioglu IH provided important technical details and revised the manuscript; Kouta KA revised the manuscript.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Ahmed Tawheed, Consultant, Department of Gastroenterology, Firat University, Elazig, Firat Campus, Elazig 23119, Türkiye. atawheed1990@gmail.com

Received: March 27, 2025
Revised: April 24, 2025
Accepted: June 13, 2025
Published online: December 20, 2025
Processing time: 130 Days and 17.4 Hours

Core Tip

Core Tip: Inflammatory bowel disease is a chronic gastrointestinal disorder causing persistent inflammation. Traditional treatments include aminosalicylates, corticosteroids, immunomodulators, and biologics. Advanced treatments like small-molecule therapies, targeted biologics, and innovative drug delivery systems have improved bioavailability and reduced side effects. Combining conventional and advanced treatments is crucial for effective treatment.